Painless liver scan could spot hidden damage in heavy drinkers with extra weight
NCT ID NCT06924281
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a quick, painless liver scan (Fibroscan®) to standard screening questions could better identify people at risk for liver disease caused by both alcohol and excess weight. Fourteen English- or Spanish-speaking adults from underserved communities took part. The goal was to see if this approach was practical and acceptable, not to provide a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
14 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be at least 21 years of age. * Exceed alcohol intake screening guidelines for MetALD. * Have a Body Mass Index (BMI) \>=25 kg/m2. * Be able to speak and read English or Spanish to provide written informed consent and understand written and oral instructions in English or Spanish. Exclusion Criteria: * Pre-existing liver disease or hepatocellular carcinoma or prior liver transplant. * Pre-existing medical conditions that, in the opinion of the investigative team, would interfere with research participation (e.g., loss of kidney function, uncontrolled infections, multiorgan failure, uncontrolled upper gastrointestinal bleeding, other active malignancies except skin cancer). * Pre-existing mental health conditions that, in the opinion of the investigative team, would interfere with the ability to provide informed consent and understand written and oral instructions (e.g., hepatic encephalopathy, psychotic disorder diagnosis or symptoms). * Current pregnancy. * Be anyone who, based on self-reported withdrawal symptoms and the opinion of the investigative team, could not currently safely be withdrawn from alcohol without medical detoxification. * Currently receiving formalized psychosocial treatment for an alcohol use or drug problem and/or newly taking medications for an alcohol use or drug problem. * Currently receiving formalized behavioral weight management treatment and/or newly taking weight loss medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Steatotic liver disease of mixed origin (metald) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Esperanza Hope Clinic
Providence, Rhode Island, 02909, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.